FDA clears HemoSonics' rapid coagulation diagnostic for hospital transfusion management

red blood cells
The tests are also important in screening for patients with hemostatic defects, which could lead to excessive bleeding during a surgical procedure. (Pixabay)

The FDA has granted a de novo clearance to HemoSonics’ point-of-care diagnostic for determining a patient’s coagulation status within 15 minutes, enabling it to respond to critical bleeding situations in the operating room and intensive care.

Previous hemostatic testing methods may take too long to be useful in such moments, leading clinicians to deliver transfusions regardless of how well patients are coagulating on their own.

The company estimates that as many as 60% of red blood cell transfusions may not be needed, or that doctors may give transfusions of inappropriate types of products such as fresh plasma versus clotting factor concentrates, platelet transfusions or other agents.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The tests are also important in screening for patients with hemostatic defects, which could lead to excessive bleeding during a surgical procedure.

HemoSonics’ cartridge-based Quantra analyzer uses ultrasound waves to measure the viscosity of a whole blood sample in a fully closed system designed for busy perioperative settings. As the blood coagulates over time within the device, its stiffness increases, which can be read by the ultrasound in a fully automated, set-it-and-forget-it procedure.

The system can also assess platelet contribution to clot stiffness, as well as the likelihood of residual heparin blood thinner in the sample. The Quantra Hemostasis Analyzer and its QPlus cartridge are now available for sale in the U.S. as well as in Europe, the company said.

“Critical bleeding occurs frequently in cardiac and major orthopedic surgeries,” HemoSonics President and CEO Timothy Fischer said in a statement. “Faster results can mean better management of critical bleeding, more cost-effective treatment, and ultimately better outcomes for patients.”

Suggested Articles

GenapSys has unveiled its compact, high-throughput DNA sequencer, alongside a $90 million venture capital raise to help jump-start its launch.

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.